Should You Forget Pfizer and Buy This Pharma Stock Instead?

AbbVie is framed as the stronger long-term hold versus Pfizer, with 2025 revenue up 8.6% to $61.2B and 2026 revenue guidance around $67B, implying 9.5% growth. Its dividend appears safer with a 65% payout ratio versus Pfizer’s 107%, and management expects adjusted EPS to rise to $14.37-$14.57 in 2026, up 44.7% at the midpoint. Pfizer faces weaker fundamentals, including 2026 revenue guidance of $59.5B-$62.5B and adjusted EPS of $2.80-$3.00, while Eliquis also approaches U.S. generic competition in 2028.

Analysis

ABBV looks like the cleaner duration trade because its earnings inflection is self-funding: the market is still pricing it as a post-Humira transition story, while the next leg is actually a free-cash-flow compounding story. The key second-order effect is multiple expansion — if investors gain confidence that a diversified immunology stack can replace a legacy blockbuster without a trough in cash generation, ABBV can re-rate toward a higher quality pharma multiple even without heroic assumptions.

PFE’s issue is not just weaker growth; it is balance-sheet encumbrance on capital allocation. A payout ratio above 100% leaves less room for R&D optionality, bolt-on M&A, or share repurchases, which means any incremental clinical disappointment or LOE pressure can hit equity holders twice: lower growth and a constrained dividend narrative. That makes the stock unusually sensitive to the next 1-2 quarters of guidance credibility, not just headline yield.

The contrarian point is that the market may be over-penalizing PFE for being “ex-growth” while underestimating the convexity of a turnaround if management can stabilize guidance and show operating leverage from prior acquisitions. Still, the burden of proof is asymmetric: ABBV needs only execution; PFE needs both execution and evidence that capital deployment is translating into sustainable revenue re-acceleration. On a 6-18 month horizon, ABBV is the higher-probability compounder, while PFE remains a value trap unless pipeline readouts and margin progression improve materially.

Key Decisions for Investors

• Long ABBV vs short PFE as a 6-12 month pair trade; target outperformance from valuation re-rating and safer capital returns, with downside limited if pharma sentiment weakens broadly because ABBV has the stronger self-help path.
• Add ABBV on any market-wide healthcare de-rating or post-earnings volatility; use a 3-6 month horizon and size for a 10-15% upside scenario if 2026 guidance confidence holds.
• Avoid initiating new outright PFE longs for dividend yield alone; the risk/reward is poor until payout ratio normalizes or forward revenue guidance inflects, which is likely a multi-quarter story.
• For income portfolios, prefer ABBV over PFE despite the lower yield; the safer dividend plus growth in FCF creates a better total-return profile over 12-24 months.
• If holding PFE, hedge with a small short or put spread into the next guidance cycle; the catalyst risk is concentrated around management proving that recent capital spending can convert into durable top-line growth.